The list of the invention of new devices is constantly increasing and hence helping the physicians to diagnose the patients and further assist them to cope with their diseases. One such invention by ViewRay, Inc. has successfully earned a 510(k) clearance from the FDA for marketing its MRIdian Linac system, which is the next-generation linear accelerator-based Magnetic resonance imaging-guided radiation therapy system.
It is first of its kind to merge an MRI with a linear accelerator to offer combined therapy as well as image guidance. It enables the physicians to observe the radiation beam is appropriately striking the tumor or not and also what can be its effect. The system is presented with a 0.35 T MRI and 6 mV linear accelerator, which functions concurrently with the aid of a shielding that safeguards the linac from the magnets.
With the MRI-guided radiation therapy, the team was able to observe the motion of organs and tumors in the body when radiation therapy is delivered to the patient and also modify the radiation dose instantaneously, and make sure that the highest dose reaches the tumor without affecting the adjacent healthy tissues. This new technique will assist the clinicians to treat tumors in the liver, pancreas, and lung where high accuracy is essential because of the close by organs and other vital structures.
ViewRay’s Chief Executive Officer and president, Chris A. Raanes, said “We believe that accessibility of the first commercial system in the world to merge a compact linear accelerator and MRI for visualization of soft tissue will head to a new medical standard of care in the field of radiation oncology. Clinical practice with the first-generation MRIdian System of ViewRay has illustrated the advantages of real-time MRI management and on-table adaptive treatment, as clinicians could actually for the first time see the movement of organs and tumor and also the way they alter their shape during the treatment course.”
Thus, the facility to perceive what is occurring within the body of a patient during the procedure of radiation therapy and also making certain that the radiation is persistently remaining on the target is a great step forward which will assist to enhance patient end results.”